Quadrant Capital Group LLC Supernus Pharmaceuticals, Inc. Transaction History

Quadrant Capital Group LLC

$1.34 Billion
Q2 2024

A detailed history of Quadrant Capital Group LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 1,471 shares of SUPN stock, worth $50,234. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,471

Previous 2,288 35.71%

Holding current value

$50,234

Previous $78,000 50.0%

% of portfolio

0.0%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$25.99 - $33.85 $21,233 - $27,655	-817 Reduced 35.71%	1,471 $39,000
Q1 2024 May 15, 2024	BUY	$27.11 - $35.17 $22,745 - $29,507	839 Added 57.9%	2,288 $78,000
Q4 2023 Feb 08, 2024	BUY	$22.72 - $29.68 $30,217 - $39,474	1,330 Added 1117.65%	1,449 $41,000
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $5,183 - $6,187	-188 Reduced 61.24%	119 $3,000
Q2 2023 Aug 09, 2023	BUY	$29.91 - $38.73 $1,136 - $1,471	38 Added 14.13%	307 $9,000
Q1 2023 May 11, 2023	BUY	$34.93 - $42.03 $3,493 - $4,203	100 Added 59.17%	269 $9,000
Q4 2022 Feb 10, 2023	SELL	$31.09 - $37.88 $11,596 - $14,129	-373 Reduced 68.82%	169 $6,000
Q3 2022 Nov 10, 2022	BUY	$28.79 - $35.41 $11,516 - $14,163	400 Added 281.69%	542 $18,000
Q2 2022 Aug 09, 2022	BUY	$25.33 - $34.25 $329 - $445	13 Added 10.08%	142 $4,000
Q4 2021 Feb 01, 2022	SELL	$26.37 - $34.22 $553 - $718	-21 Reduced 14.0%	129 $4,000
Q3 2021 Nov 12, 2021	BUY	$23.54 - $31.39 $329 - $439	14 Added 10.29%	150 $4,000
Q2 2021 Aug 09, 2021	BUY	$26.72 - $33.19 $187 - $232	7 Added 5.43%	136 $4,000
Q4 2020 Feb 16, 2021	BUY	$17.7 - $25.81 $371 - $542	21 Added 19.44%	129 $3,000
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $679 - $1,160	47 Added 77.05%	108 $2,000
Q3 2019 Oct 24, 2019	SELL	$25.47 - $33.37 $20,299 - $26,595	-797 Reduced 92.89%	61 $1,000
Q2 2019 Jul 24, 2019	BUY	$29.96 - $38.87 $23,878 - $30,979	797 Added 1306.56%	858 $28,000
Q3 2018 Oct 29, 2018	SELL	$42.7 - $56.55 $1,622 - $2,148	-38 Reduced 38.38%	61 $3,000
Q2 2018 Aug 09, 2018	BUY	$44.1 - $59.85 $1,675 - $2,274	38 Added 62.3%	99 $5,000
Q1 2018 May 10, 2018	SELL	$37.15 - $46.9 $1,597 - $2,016	-43 Reduced 41.35%	61 $2,000
Q3 2017 Oct 13, 2017	BUY	$36.75 - $49.65 $1,580 - $2,134	43 Added 70.49%	104 $3,000
Q2 2017 Aug 15, 2017	BUY	N/A	61	61 $0

Others Institutions Holding SUPN

# of Institutions

259

Shares Held

59.3M

Call Options Held

47.9K

Put Options Held

13.1K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.83B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.

Account

Quadrant Capital Group LLC Supernus Pharmaceuticals, Inc. Transaction History